NR3C1 and demyelinating disease: Mei and colleagues paved the way for other research groups that employed similar strategies and reported ‘new uses for old drugs’, such as clobetasol (glucocorticoid receptors agonist) [19], miconazole (MAPK route activator) or taurine [20,21], for the hypothetical treatment of demyelinating diseases.